To the Editor The CHOICE trial1 is the first randomized trial comparing balloon-expandable and self-expandable valves for TAVR. This trial used the VARC definition of device success as a composite primary end point. It found a higher device success with the balloon-expandable valve, driven largely by a lower frequency of aortic regurgitation. There are several serious flaws in the trial design that call these conclusions into question.
Reardon MJ. Bioprosthetic Valves for Transcatheter Aortic Valve Replacement. JAMA. 2014;312(8):844–845. doi:10.1001/jama.2014.8364
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: